4-(3-chlorophenyl)-N-(4-propan-2-ylphenyl)piperazine-1-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(3-chlorophenyl)-N-(4-propan-2-ylphenyl)piperazine-1-carboxamide
• 化学式: C₂₀H₂₄ClN₃O
• 分子量: 357.9
• InChiKey: HEVGKWFLDSGQFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES
  申请人：St. Jude Children's Research Hospital, Inc.

  公开号：EP3474667A1

  公开（公告）日：2019-05-01
• METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR
  申请人：ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

  公开号：US20210023081A1

  公开（公告）日：2021-01-28

  The present disclosure relates to methods of treating a coenzyme A reduction, elevation, sequestration, toxicity, or redistribution (CASTOR) disease such as, for example, defects in fatty acid oxidation enzymes, methylmalonic acidemia, glutaric acidemia, propionic academia, and HMG-CoA lyase, via small molecule modulators of CoA levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
• [EN] SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES<br/>[FR] MODULATEURS À PETITES MOLÉCULES DES PANTOTHÉNATE KINASES
  申请人：ST JUDE CHILDREN'S RES HOSPITAL

  公开号：WO2017223474A1

  公开（公告）日：2017-12-28

  The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
• [EN] METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR<br/>[FR] MÉTHODES DE TRAITEMENT DE TROUBLES ASSOCIÉS À CASTOR
  申请人：[en]ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

  公开号：WO2022133034A1

  公开（公告）日：2022-06-23

  The present disclosure relates to methods of identifying subjects in need of treatment for, e.g., a coenzyme A reduction, elevation, sequestration, toxicity, or redistribution (CASTOR) disease such as, for example, defects in fatty acid oxidation enzymes, methylmalonic acidemia, glutaric acidemia, propionic academia, and HMG-CoA lyase, via small molecule modulators of CoA levels. The methods may comprise assessing levels of carnitines, CoA, and/or various metabolites and biomarkers and administration of therapeutics useful in the treatment of CASTOR disorders, metabolic diseases, and/or neurological diseases. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present inventions.